Zykadia gets new lung cancer indication

Country

Switzerland

The Novartis tyrosine kinase inhibitor Zykadia (ceritinib) has been approved in the US for the first-line treatment of ALK-positive non-small cell lung cancer following Phase 3 data that showed a significant improvement in progression free survival in patients with the disease.